Genmab A/S shares have observed fluctuation as market sentiments vary. Despite several case studies providing a
Buy rating, the company's stock nonetheless dips on the announcement of collaboration termination with BioNTech and same goes for an unexpected selling of shares by a board member. Notwithstanding these incidents, substantial investment firms such as
Envestnet Asset Management Inc., Renaissance Technologies LLC, and Oppenheimer Asset Management Inc., continue to believe in Genmab's financial strength, with the latter two even increasing their stock holdings.
Morgan Stanley iterates that there exist certain ambiguities but values the stock potential. Genmab stays positive about its proficient
2024 revenue and earnings however, Truist reduces the price target slightly. Despite a drop due to preliminary data from a lung cancer study, the company announces capital boosts from warrants exercises. Genmab has been actively involved in
share buy-back programs. Despite the recent
$2.9 billion Q2 sales from DARZALEX, of which Genmab earns royalties, the company's collaboration with Johnson & Johnson disappoints the bio-tech field on lung cancer drug data.
Genmab Stocks News Analytics from Wed, 29 May 2019 07:00:00 GMT to Sun, 22 Sep 2024 16:03:46 GMT -
Rating 4
- Innovation 2
- Information 7
- Rumor -2
